Sweden: Aqilion issue in kind marks final instalment of Regulus acquisition from LEO Pharma

Aqilion, a biotech company that focuses on developing new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions, has resolved on an issue in kind in accordance with the acquisition of the Regulus programme from LEO Pharma at the end of 2021. Under the agreement with LEO Pharma, Aqilion is to pay a…

You must be a HMI Subscriber to view this content.

Subscribe Now »